Applied dna files provisional patent applications for methods of double-stranded rna mitigation in next-generation mrna production

Stony brook, ny / accesswire / august 23, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced the filing with the united states patent and trademark office of two provisional patent applications claiming compositions of matter and methods to reduce or potentially eliminate double-stranded rna (dsrna) byproducts generated during the production of mrna therapeutics. dsrna is a widespread problematic impurity that can cause adverse reactions to mrna therapies and is currently removed or mitigated using specialized purification instruments that reduce yields and increase manufacturing costs.
APDN Ratings Summary
APDN Quant Ranking